Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand https://ift.tt/nDyRE7T

Philogen, a Swiss-Italian firm, is developing it for the treatment of melanoma and non-melanoma skin cancers. Under the terms of the agreement, the Mumbai-based drug major will have exclusive rights to commercialise Nidlegy. Philogen will complete pivotal clinical trials for the product in Europe, pursue marketing authorisation with the regulatory authorities and manufacture commercial supplies.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/XwgV4T2